Morgan Lewis

Related Publications

2001 Genetic Transplantation Cloning Federal Legislation: Some Constitutional Issues, Journal of Science and Technology Law
View all publications
Print Profile

Fahd M.T. Riaz
Associate


Email: friaz@morganlewis.com
Philadelphia
1701 Market St.
Philadelphia, PA 19103-2921
Phone: 215.963.5372
Fax: 215.963.5001

Fahd M.T. Riaz is an associate in Morgan Lewis's Business and Finance Practice. Mr. Riaz has served as lead counsel for pharmaceutical and biotech companies in a number of large life sciences industry transactions. In addition to providing general corporate and transactional advice, Mr. Riaz's practice focuses particularly on fulfilling the special business and legal needs of public and private life sciences companies as they seek to form joint ventures, partnerships, and other complex collaborations; acquire venture capital financing; and execute mergers, acquisitions, divestitures, and licensing agreements.

Mr. Riaz's clients range from early-stage biotechnology startups to global pharmaceutical companies, as well as medical device and other technology companies. Drawing upon his technical background as a molecular biologist, he advises and provides an assortment of services for these clients in support of a variety of mission-critical undertakings, including the negotiation and structuring of transactions, the facilitation of equity investments, and the navigation of other securities matters that often accompany such transactions. Related matters include the negotiation and drafting of technical contractual arrangements related to the conducting and outsourcing of drug discovery, development, manufacturing and supply, and marketing. Mr. Riaz also advises boards of directors on disclosure issues, corporate communications policies, and fiduciary duty matters.

Mr. Riaz is admitted to practice in Pennsylvania, Michigan, New York, and Massachusetts.

Selected Representations

  • Shire Pharmaceuticals in its up to $440 million collaboration with Amicus Therapeutics for the development and commercialization of three therapies for genetic disorders
  • EUSA in its acquisition of Collatamp G Implant product and License of two other products in development
  • Solstice in its Development and Commercialization of Neurobloc in Europe providing 41 Million Euros in upfront and milestone payments and development partner
  • Velcera in its global licensing agreement with Novartis for its oral mucosal canine promist formulation
  • Summers Laboratories in its divestiture of its Lice Asphyxiation Product to Sciele Pharma
  • Prism in raising up to $68 million through equity and royalty/revenue monetization
  • Solstice in raising $85 million in equity and debt financing
  • SANKYO in its up to $320 million collaboration and development with KAI Pharmaceuticals for its delta protein kinase C inhibitor, KAI-9803

Education

  • Boston University School of Law, 2002, J.D., Cum Laude
  • State University of New York at Buffalo, 1997, B.S., Cum Laude